P155 Super accelerated course of hepatitis B Vaccine—10 years on, is it working?

Background In 2002 the super-accelerated hepatitis B vaccination schedule was introduced in GUM clinics. At that time an audit was undertaken in our department to evaluate completion of the vaccination schedule. Aim This study aims to see if and why things have changed 10 years on? Methods A computer search of those coded with P2 identified the first 100 patients who commenced hepatitis B vaccination from April 2011. Notes were analysed and data collected on indication for vaccination, number of vaccines administered and whether serological response to vaccine was measured. Results were then compared to the previous study done in 2002. Results In 2002, 116 patients commenced hepatitis B vaccination over a 12-month period; in 2011 there were 298. Five patients were excluded from the study as serological testing showed they were already immune or had active infection. The abstract P155 table 1 below shows the number of vaccines each person received. The proportion of MSM receiving three vaccines was 51.6%. Abstract P155 Table 1 Comparison of number of Hepatitis B vaccines completed 2002 2011 1 vaccine only 9.5% 15.8% 2 vaccines only 18.1% 24.2% 3 vaccines 72.4% 60% Serological response measured 33.6% 29.4% Discussion The number of people being vaccinated against hepatitis B has increased significantly over 10 years in keeping with increased patient numbers. However the proportion of people completing three vaccines has significantly reduced, especially in MSM. This study has prompted us to look at the information and explanation given to patients before commencing an immunisation schedule. In addition, to improve compliance we will be encouraging each patient to make future appointments at initial visit. As automatic appointment SMS messages are sent out 24 h in advance, making appointments ensures a timely reminder of the due dose is sent. All patients should also receive written information about hepatitis B vaccination. With these measures in place we will hopefully improve patient uptake of all three hepatitis B vaccines. Future audit will see if we have been successful!